Vaxcyte, Inc. (PCVX)
46.85
+0.52
(+1.12%)
USD |
NASDAQ |
Jun 09, 16:00
46.86
0.00 (0.00%)
After-Hours: 20:00
Vaxcyte SG&A Expense (Quarterly) : 33.07M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | 28.24M |
| Revolution Medicines, Inc. | 101.25M |
| Vera Therapeutics, Inc. | 39.12M |
| Erasca, Inc. | 10.65M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |